ArticleInfection and drug resistance2026
Mechanistic Insights into Maxing Shigan Decoction in Community-Acquired Pneumonia Based on Bioinformatics and Experimental Validation.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the mechanisms of Maxing Shigan Decoction (MXSGD) in community-acquired pneumonia (CAP) via network pharmacology, machine learning, molecular docking, and experimental validation. Methods: MXSGD active compounds and targets were collected from TCMSP and TCM-ID; CAP-related genes were obtained from GEO datasets, and integrated with targets from GeneCards, OMIM, DisGeNET, and TTD. Overlapping targets were subjected to PPI, GO, and KEGG analyses. LASSO and SVM-RFE were used to select feature genes, and six core targets with robust diagnostic performance (AUC > 0.8 in both training and validation sets) were identified after ROC evaluation. Immune infiltration, GSEA, molecular docking, and 100 ns molecular dynamics simulations were performed. In vivo, the efficacy of MXSGD was assessed in a clinically relevant influenza A virus- Results: We obtained 139 active compounds, 867 MXSGD targets, and 4,444 CAP genes, yielding 262 shared targets enriched in immune-inflammation pathways. Six core targets with high diagnostic accuracy were identified: ABCB1 (AUC = 0.9072), KIT (AUC = 0.8072), PLA2G7 (AUC = 0.8391), SLC2A3 (AUC = 0.9372), PRF1 (AUC = 0.8082), and GPR18 (AUC = 0.8414). Immune infiltration revealed eight differentially abundant immune cell types. Molecular docking and molecular dynamics supported the stable binding of glabridin to KIT and SLC2A3. In vivo, MXSGD significantly ameliorated lung pathological injury, reduced lung index and serum IL-6 and TNF-α levels (FDR-adjusted Conclusion: These results suggest that MXSGD may exert immunomodulatory and anti-inflammatory effects in CAP, potentially by regulating ABCB1, KIT, PLA2G7, SLC2A3, PRF1, and GPR18; however, only three of these (KIT, GPR18, and SLC2A3) showed statistically significant mRNA changes. These findings provide a multi-component, multi-target rationale requiring further experimental and clinical confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.